{"entity":{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","aka":[],"tldr":"Led ECHELON-2, the first trial to improve survival in peripheral T-cell lymphoma, using brentuximab vedotin.","summary":"Steven Horwitz was principal investigator of ECHELON-2, which showed brentuximab vedotin plus CHP improves progression-free and overall survival compared with CHOP in CD30-positive peripheral T-cell lymphoma, the first randomised survival benefit in the disease. He has led trials of pralatrexate, romidepsin, duvelisib and other agents in T-cell lymphomas and leads the T-cell lymphoma programme at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Horwitz%20SM%5BAuthor%5D%20T-cell%20lymphoma"}],"tags":["lymphoma","t-cell","adc"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["brentuximab-vedotin"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Attending Physician, Lymphoma Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Peripheral T-cell lymphoma","Cutaneous T-cell lymphoma","Antibody-drug conjugates","Novel agents"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Horwitz%20SM%5BAuthor%5D%20T-cell%20lymphoma"}],"papers":[{"title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(18)32984-2"},{"title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","journal":"Annals of Oncology","year":2022,"doi":"10.1016/j.annonc.2021.12.002"}],"orcid":"0000-0002-6399-2006"},"route":"/people/steven-horwitz/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/"}]}}